The efficacy of moboxetinib in the second-line treatment of lung cancer

Mobocertinib is a drug used to treat a specific type of lung cancer: epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). It belongs to a class of drugs called tyrosine kinase inhibitors.

The effectiveness of mobosetinib as a second-line treatment for lung cancer has been demonstrated in clinical trials. An early clinical trial called the "EXCLAIM" study showed that mobosetinib showed certain efficacy in patients with NSCLC. The study included patients who had previously received treatment with other EGFR inhibitors but developed resistance.

According to the results of the study, mobosetinib demonstrated significant overall response rate and duration in NSCLC patients. The study results showed that the overall response rate of mobosetinib in these patients was 28.3%, and a considerable number of patients had responses that lasted longer than 6 months. In addition, the adverse reactions of the drug are relatively controllable, with most adverse reactions being mild to moderate.

Mobosetinib The original drug is currently on the market in China and has not yet been included in the medical insurance. SpecificationThe price of 40mg*112 pills per box is about 40,000 yuan, which is very expensive.The Hong Kong version of the original drug Specifications40mg*30 pills per box is priced at more than 7,000 yuan (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. The drug ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory40mg*120 pills per boxThe pricemay be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.